Skip to main content

Kaisheng New Materials

MaterialsZibo, Shandong, ChinaFounded 2005· One of 1021 Materials companies tracked by AMPulse

Shandong Kaisheng New Materials is a Chinese public company (SZSE: 301069) producing fine chemicals and PEKK (polyetherketoneketone) resin, expanding PEKK use into aerospace, medical implant, and additive manufacturing applications.

CEO / Founder
Wang Jiarong (王加荣)
Team Size
501-1000
Stage
Public
Total Funding
$140M
Latest Round
Post-IPO

Technology & Products

Key Products

PEKK resin and pellets; aramid polymerization monomers (isophthaloyl chloride, terephthaloyl chloride); thionyl chloride; other chlorinated fine chemicals; new lithium salt materials for batteries.

Technological Advantage

Proprietary one-step PEKK synthesis route; vertically integrated chlorinated fine-chemical and aramid monomer production feeding PEKK value chain; domestic leadership in thionyl chloride and aromatic polyamide monomers.

Differentiation

Value Proposition

Domestic first-mover in mass-produced PEKK resin via a proprietary one-step synthesis process claimed to offer a cost advantage over established Western PEKK suppliers, now extending into high-temperature, high-strength applications for aerospace brackets, medical implants, and SLS additive manufacturing.

How They Differentiate

Claims a lower-cost one-step PEKK synthesis process versus multi-step routes used by Western incumbents, backed by existing scale in adjacent chlorinated fine chemicals; has not yet confirmed qualified spherical PEKK powder for SLS.

Market & Competition

Target Customers

Downstream manufacturers in aerospace, medical device, aramid fiber, lithium battery, and specialty chemical industries; early-stage AM material test customers.

Industry Verticals

Aerospace, Medical Devices, Additive Manufacturing, Lithium Battery, High-Performance Fibers (Aramid), Agrochemicals, Food Additives

Competitors

Arkema (Kepstan PEKK); Victrex; Oxford Performance Materials

Growth & Milestones

Growth Metrics

2023 revenue ¥987M, total assets ¥2.48B, debt-to-asset ratio below 16.87%; R&D spend ¥53.8M (2024) vs ¥51.5M (2023); 2025 net profit up 129% YoY per 2025 annual report; ~868 employees.

Major Milestones

Founded Dec 2005; became China's first company to achieve PEKK mass production; IPO on Shenzhen ChiNext Sept 2021 raising ¥310.2M (stock code 301069.SZ); issued ¥650M convertible bonds Nov-Dec 2023 for a new lithium-salt project; re-elected Chairman Wang Jiarong to 4th Board term June 2025-2028; in a Sept 2026 shareholder Q&A confirmed optimization of one-step PEKK synthesis and shipment of test samples to aerospace/medical/AM customers, while vertical integration into spherical SLS powder remains unconfirmed.

Notable Customers

DuPont, Teijin, Taihe New Material (aramid monomer customers); undisclosed aerospace, medical, and additive-manufacturing customers received PEKK test samples per company investor disclosure.

Recent coverage of Kaisheng New Materials